SCHEMBL6154489

SCHEMBL6154489

S=C=NC1Cc2ccccc2C1

nearest known ligand 0.44

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.44
NAAA Q02083 4/20 0.39
IDO1 P14902 3/20 0.37
ANPEP P15144 1/20 0.35
MIF P14174 1/20 0.34
PLAU P00749 1/20 0.34
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HRH1 P35367 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30724669 1.00 APLNR (0.44) APLNRNAAAIDO1ANPEPMIF
SCHEMBL29433031 0.86 PLAU (0.46) APLNRANPEPPLAU
SCHEMBL6953544 0.86 PLAU (0.46) APLNRANPEPPLAU
SCHEMBL1193046 0.77 ANPEP (0.39) IDO1ANPEPPLAU
SCHEMBL11491487 0.72 GRIN2D (0.37) IDO1HTR2A
SCHEMBL25311061 0.69 CHRM2 (0.38) NAAA
SCHEMBL4670580 0.69 OPRM1 (0.37) HTR2AHTR2C
SCHEMBL3947057 0.69 IDO1 (0.41) IDO1PLAU
SCHEMBL14231826 0.69 IDO1 (0.41) IDO1ANPEPPLAU
SCHEMBL4701299 0.68 RET (0.42) IDO1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692083-A1 NOVEL AZABICYCLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN, COMPRISING SAME Nextgen Bioscience Co., Ltd. (KR) 2026-02-11 EP disclosed
US-12145929-B2 Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same NEXTGEN BIOSCIENCE CO., LTD. (KR) 2024-11-19 US disclosed
WO-2024205327-A1 NOVEL AZABICYCLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN, COMPRISING SAME 주식회사 넥스트젠바이오사이언스 2024-10-03 WO disclosed
US-20240279216-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME NEXTGEN BIOSCIENCE CO., LTD. (KR) 2024-08-22 US disclosed
EP-4353720-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME Nextgen Bioscience Co., Ltd. (KR) 2024-04-17 EP disclosed
CN-117396471-A Novel piperidine derivatives and pharmaceutical compositions for inhibiting autotaxin comprising the same 株式会社次代生物科学 2024-01-12 CN disclosed
WO-2023055178-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME 주식회사 넥스트젠바이오사이언스 2023-04-06 WO disclosed
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 US disclosed
EP-1446110-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES Structural Bioinformatics Inc. (US) 2004-08-18 EP disclosed
WO-2003032916-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES STRUCTURAL BIOINFORMATICS INC. (US) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279216-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME ENPP2, UACA, ITCH APLNR 780/4885NAAA 1187/4885IDO1 588/4885
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases PTPRS, PTPRJ, PTPRCAP APLNR 3829/4885NAAA 4435/4885IDO1 1533/4885
US-12145929-B2 Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same ENPP2, UACA, ACAT2 APLNR 727/4885NAAA 877/4885IDO1 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.